{
  "docId": "019de071-7055-71be-8e36-ff3241c1e380",
  "docSlug": "06f5a1d0d7573c1d13069d999ff5f2e2",
  "documentTitle": "RenovoRx | IPO Presentation Deck | 29 slides",
  "authorId": "renovorx",
  "authorName": "RenovoRx",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 21,
  "pageCount": 29,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide outlines a clear regulatory and clinical strategy for a medical device/drug trial.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-7055-71be-8e36-ff3241c1e380/21",
  "deckHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380",
  "deckJsonHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380.json",
  "deckAnchorHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "callout",
      "text": "3rd party KOL interviews -> 4-month survival benefit is threshold for deep market adoption",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb2069ae-2f76-460e-bc41-526344d57a46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "FDA Pre-IND meeting: FDA confirmed study design and proposed endpoints; Indicated that this Phase 3 study should result in New Drug Application approval if significant survival benefit is demonstrated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5274dc7b-2a71-47a4-8023-c9eeb15dd1a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.7,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "TIGeR-PaC Phase 3 trial is a multi-center, open-label, randomized, active-controlled study. Population: 340 subjects with LAPC. Primary endpoint: hard endpoint of overall survival (From time of randomization until death). Secondary endpoints include: Quality of life (QoL) questionnaire results; Progression free survival",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f08a085-4f19-4149-ae45-e66dc10c0f85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Phase 1/2 + observational registry data -> successful FDA IND application to launch Phase 3 IND study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4054a109-9303-44e5-ad5a-7279fd413422",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Designed for Success: Expect One Phase 3 Trial Will Lead to FDA Approval and Commercial Adoption",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ab05ce3-7eb8-4776-a26d-56dcc8a9da38",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e74d95e8-3a14-4b2a-b9f2-45df66c99864",
      "evidence": "Attention capture through 'Designed for Success'",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "eeb5d12f-412a-4325-8fbd-2a39f305b6d7",
      "evidence": "Slides 4 and 28 present the executive summary and investment highlights",
      "position": 1,
      "objective": "Present the investment highlights and ask",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}